Study Links Five Infections to Over 2 Million New Cancer Cases Annually
Cancer is often seen as an unavoidable part of life, but a new study published in The Lancet Oncology sheds light on how infections significantly contribute to cancer risk. The research, conducted by a team of cancer epidemiologists, indicates that infections were linked to 12 percent of all cancer diagnoses in 2024, translating to approximately 2.3 million new cases. This study highlights five key pathogens responsible for the majority of these infection-related cancers.
The most prevalent pathogen identified was Helicobacter pylori, a stomach bacterium implicated in 4 percent of total cancer cases, equating to around 760,000 diagnoses. H. pylori is notably common, with statistical estimates suggesting that about half of the global population is infected. While many individuals remain asymptomatic, certain strains can lead to gastric ulcers and, ultimately, stomach cancer.
The human papillomavirus (HPV) was also linked to 4 percent of new cancer cases, accounting for approximately 750,000 diagnoses. Other pathogens included hepatitis B virus (HBV), which contributed to 2 percent of new cases, Epstein-Barr virus (EBV) at 1 percent, and hepatitis C virus (HCV), which was linked to less than 1 percent. Notably, EBV has recently gained recognition for its cancer-causing potential, with increasing evidence supporting its role in oncogenesis.
These findings are alarming, as they reveal that infections, which can cause significant health issues on their own, are also linked to cancer development. However, they also present an opportunity for intervention. The study's lead author, Harriet Rumgay, emphasizes the importance of infection control in global cancer prevention strategies. Many of the infectious agents identified have existing preventive measures, including vaccines and treatments, which could significantly impact cancer rates if effectively implemented.
Despite advancements in vaccination and screening, infection-related cancers continue to pose a major challenge, particularly in low-income and middle-income countries. The research indicates that three-quarters of infection-related cancers occur in these regions, with eastern Asia alone accounting for 42 percent of the global total. The primary pathogens responsible for these diagnoses are mainly H. pylori and HBV.
Increasing vaccination rates for HPV, particularly among men who have historically been under-targeted for HPV vaccines, could lead to a substantial reduction in global cancer rates. However, addressing H. pylori is more complex, as there has been limited progress in developing effective vaccines or therapies to control this bacterium, which is crucial for reducing gastric cancer incidence.
Currently, there are no vaccines or effective methods to control EBV, although several clinical trials are underway. The authors of the study stress that while investment in new preventive vaccines for EBV, H. pylori, and other cancer-linked viruses is essential, many known prevention strategies are cost-effective yet underutilized due to societal, financial, and political barriers, particularly in the regions that need them the most.
Given the significant economic and social costs associated with cancer, prioritizing investment in prevention is crucial. The research underscores the need for a concerted effort to improve public health interventions aimed at reducing infection-related cancer cases globally.




